EU's CHMP recommends Pharming's Ruconest for HAE
This article was originally published in Scrip
The EU's CHMP has recommended marketing authorisation of Pharming's C1 esterase inhibitor Ruconest (also known as Rhucin and conestat alfa) for the treatment of acute angioedema attacks in adult patients with hereditary angioedema (HAE).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.